Growth factors and trefoil peptides in gastrointestinal health and disease

Current Opinion in Pharmacology

Volumn 4, Issue 6, 2004, Pages 567-571

  Playford, Raymond J ^a   Ghosh, Subrata ^a   Mahmood, Asif ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GLUCAGON LIKE PEPTIDE 2; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; GROWTH HORMONE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IMMUNOTOXIN; IRINOTECAN; KERATINOCYTE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SYNTHETIC PEPTIDE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TREFOIL PEPTIDE; UNINDEXED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INVASION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CANCER; CROHN DISEASE; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG RECEPTOR BINDING; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE MUCOSA; LOW DRUG DOSE; LUNG CANCER; METASTASIS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SHORT BOWEL SYNDROME; SIGNAL TRANSDUCTION; SKIN TOXICITY; TISSUE ENGINEERING; TISSUE REPAIR; TUMOR VASCULARIZATION; ULCERATIVE COLITIS;

ANIMALS; BIOTECHNOLOGY; CHEMISTRY, PHARMACEUTICAL; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; GROWTH SUBSTANCES; HUMANS; MUCINS; MUSCLE PROTEINS; PEPTIDES; TECHNOLOGY, PHARMACEUTICAL;

EID: 13944284614     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.05.004     Document Type: Review

References (50)

1. J.M. Rhoads R.A. Argenzio W. Chen R.A. Rippe J.K. Westwick A.D. Cox H.M. Berschneider D.A. Brenner L-glutamine stimulates intestinal cell proliferation and activates mitogen-activated protein kinases Am J Physiol 272 1997 G943-G953
2. J.J. Boza D. Moennoz C.E. Bournot S. Blum I. Zbinden P.A. Finot O. Ballevre Role of glutamine on the de novo purine nucleotide synthesis in Caco-2 cells Eur J Nutr 39 2000 38-46
3. T.R. Ziegler M.E. Evans C. Fernandez-Estivariz D.P. Jones Trophic and cytoprotective nutrition for intestinal adaptation, mucosal repair, and barrier function Annu Rev Nutr 23 2003 229-261
4. R.J. Playford T. Marchbank R. Chinnery R. Evison M. Pignatelli R.A. Boulton L. Thim A.M. Hanby Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration Gastroenterology 108 1995 108-116
5. R.J. Playford Trefoil peptides: What are they and what do they do J R Coll Physicians Lond 31 1997 37-41
6. A. Ouban P. Muraca T. Yeatman D. Coppola Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas Hum Pathol 34 2003 803-808
7. G. Furstenberger H.J. Senn Insulin-like growth factors and cancer Lancet Oncol 3 2002 298-302
8. M. Sekharam A. Nasir H.E. Kaiser D. Coppola Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro Anticancer Res 23 2003 1517-1524
9. L pathway Cancer Res 63 2003 7708-7716
10. M.E. Street F. Miraki-Moud I.R. Sanderson M.O. Savage G. Giovannelli S. Bernasconi C. Camacho-Hubner Interleukin-1β (IL-1β) and IL-6 modulate insulin-like growth factor-binding protein (IGFBP) secretion in colon cancer epithelial (Caco-2) cells J Endocrinol 179 2003 405-415
11. E.J. Kim I.J. Kang H.J. Cho W.K. Kim Y.L. Ha J.H. Park Conjugated linoleic acid downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells J Nutr 133 2003 2675-2681
12. E.K. Maloney J.L. McLaughlin N.E. Dagdigian L.M. Garrett K.M. Connors X.M. Zhou W.A. Blattler T. Chittenden R. Singh An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation Cancer Res 63 2003 5073-5083
13. V. Easwaran S.H. Lee L. Inge L. Guo C. Goldbeck E. Garrett M. Wiesmann P.D. Garcia J.H. Fuller V. Chan et al. β-Catenin regulates vascular endothelial growth factor expression in colon cancer Cancer Res 63 2003 3145-3153
14. Y. Mizukami J. Li X. Zhang M.A. Zimmer O. Iliopoulos D.C. Chung Hypoxia inducible factor-1 independent regulation of vascular endothelial growth factor by hypoxia in colon cancer Cancer Res 64 2004 1765-1772
15. R. Fukuda B. Kelly G.L. Semenza Vascular endothelial growth factor gene expression in colon cancer cell exposed to prostaglandin E2 is mediated by hypoxia inducible factor-1 Cancer Res 63 2003 2330-2334
16. R. Kopp E. Rothbauer M. Ruge H. Arnholdt J. Spranger M. Muders D.G. Pfeiffer F.W. Schildberg A. Pfeiffer Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: Evidence for new therapeutic options Recent Results Cancer Res 162 2003 115-132
17. A.A. Khorana C.K. Ryan C. Cox S. Eberly D.M. Sahasrabudhe Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: A role for the host response in prognosis Cancer 97 2003 960-968
18. R. Kopp E. Rothbauer E. Mueller F.W. Schildberg K.W. Jauch A. Pfeiffer Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels Dis Colon Rectum 46 2003 1391-1399
19. Y. Yamanaka H. Friess M.S. Kobrin M. Buchler H.G. Beger M. Korc Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness Anticancer Res 13 1993 565-569
20. A. Karameris P. Kanavaros D. Aninos V. Gorgoulis G. Mikou T. Rokas M. Niotis N. Kalogeropoulos Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas Pathol Res Pract 189 1993 133-137
21. L.F. Allen I.A. Eiseman D.W. Fry P.F. Lenehan CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer Semin Oncol 30 2003 65-78
22. R.S. Herbst D.M. Shin Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy Cancer 94 2002 1593-1611
23. N.A. Reynolds A.J. Wagstaff Cetuximab: In the treatment of metastatic colorectal cancer Drugs 64 2004 109-118
24. L.B. Saltz N.J. Meropol P.J. Loehrer M.N. Needle J. Kopit R.J. Mayer Phase II trial of Cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1177-1179
25. D. Cunningham Y. Humblet S. Siena D. Khayat H. Bleiberg A. Santoro D. Bets M. Mueser A. Harstrick C. Verslype I. Chau E. Van Cutsem Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) N Engl J Med 351 2004 337-345
26. N. Ferrara K.J. Hillan H.P. Gerber W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 2004 391-400
27. M.S. Abaza R.J. Al-Attiyah A.M. Al-Saffar S.M. Al-Sawan N.M. Moussa Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells Tumour Biol 24 2003 241-257
28. J. Berlanga P. Prats D. Remirez R. Gonzalez P. Lopez-Saura J. Aguiar M. Ojeda J.J. Boyle A.J. Fitzgerald R.J. Playford Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage Am J Pathol 161 2002 373-379
29. M.E. Caballero J. Berlanga D. Ramirez P. Lopez-Saura R. Gozalez D.N. Floyd T. Marchbank R.J. Playford Epidermal growth factor reduces multiorgan failure induced by thioacetamide Gut 48 2001 34-40
30. M.D. Halpern J.A. Dominguez K. Dvorakova H. Holubec C.S. Williams Y.G. Meza M.C. Ruth B. Dvorak Ileal cytokine dysregulation in experimental necrotizing enterocolitis is reduced by epidermal growth factor J Pediatr Gastroenterol Nutr 36 2003 126-133
31. H. Schulze-Bergkamen D. Brenner A. Krueger D. Suess S.C. Fas C.R. Frey A. Dax D. Zink P. Buchler M. Muller P.H. Krammer Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt Hepatology 39 2004 645-654
32. J.S. Thompson Epidermal growth factor and the short bowel syndrome JPEN J Parenter Enteral Nutr 23 1999 S113-S116
33. L.E. Stern C.R. Erwin D.P. O'Brien F. Huang B.W. Warner Epidermal growth factor is critical for intestinal adaptation following small bowel resection Microsc Res Tech 51 2000 138-148
34. W.F. Johnson C.R. DiPalma T.R. Ziegler S. Scully C.L. Farrell Keratinocyte growth factor enhances early gut adaptation in a rat model of short bowel syndrome Vet Surg 29 2000 17-27
35. H. Yang B.E. Wildhaber D.H. Teitelbaum Keratinocyte growth factor improves epithelial function after massive small bowel resection JPEN J Parenter Enteral Nutr 27 2003 198-206
36. M.B. Gillingham E.M. Dahly S.G. Murali D.M. Ney IGF-I treatment facilitates transition from parenteral to enteral nutrition in rats with short bowel syndrome Am J Physiol Regul Integr Comp Physiol 284 2003 R363-R371
37. P.B. Jeppesen B. Hartmann J. Thulesen J. Graff J. Lohmann B.S. Hansen F. Tofteng S.S. Poulsen J.L. Madsen J.J. Holst P.B. Mortensen Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon Gastroenterology 120 2001 806-815
38. D.A. Litvak M.R. Hellmich B.M. Evers N.A. Banker C.M. Townsend Jr. Glucagon-like peptide 2 is a potent growth factor for small intestine and colon J Gastrointest Surg 2 1998 146-150
39. D. Seguy K. Vahedi N. Kapel J.C. Souberbielle B. Messing Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: A positive study Gastroenterology 124 2003 293-302
40. F. Beck K. Chawengsaksophak P. Waring R.J. Playford J.B. Furness Reprogramming of intestinal differentiation and intercalary regeneration in Cdx2 mutant mice Proc Natl Acad Sci USA 96 1999 7318-7323
41. F. Beck K. Chawengsaksophak J. Luckett S. Giblett J. Tucci J. Brown R. Poulsom R. Jeffery N.A. Wright A study of regional gut endoderm potency by analysis of Cdx2 null mutant chimaeric mice Dev Biol 255 2003 399-406
42. C. Bonhomme I. Duluc E. Martin K. Chawengsaksophak M.P. Chenard M. Kedinger F. Beck J.N. Freund C. Domon-Dell The Cdx2 homeobox gene has a tumour suppressor function in the distal colon in addition to a homeotic role during gut development Gut 52 2003 1465-1471
43. Z. Khan C. Macdonald A.C. Wicks M.P. Holt D. Floyd S. Ghosh N.A. Wright R.J. Playford Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis Aliment Pharmacol Ther 16 2002 1917-1922
44. A. Sinha J.M. Nightingale K.P. West J. Berlanga-Acosta R.J. Playford Epidermal growth factor (EGF) enemas treat ulcerative colitis N Engl J Med 349 2003 350-357
45. W.J. Sandborn B.E. Sands D.C. Wolf J.F. Valentine M. Safdi S. Katz K.L. Isaacs L.D. Wruble J. Katz D.H. Present et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: A randomized, double-blind, placebo-controlled, dose-escalation trial Aliment Pharmacol Ther 17 2003 1355-1364
46. G. Xia A.E. Martin G.E. Besner Heparin-binding EGF-like growth factor downregulates expression of adhesion molecules and infiltration of inflammatory cells after intestinal ischemia/reperfusion injury J Pediatr Surg 38 2003 434-439
47. A. Bedirli I. Soyuer S. Muhtaroglu I. Guler Role of granulocyte-macrophage colony-stimulating factor on apoptosis induced by ischemia-reperfusion in the intestinal epithelium Eur Surg Res 35 2003 357-362
48. S. Rodrigues S. Attoub Q.D. Nguyen E. Bruyneel C.M. Rodrigue B.R. Westley F.E. May L. Thim M. Mareel S. Emami C. Gespach Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells Oncogene 22 2003 4488-4497
49. M. Clyne P. Dillon S. Daly R. O'Kennedy F.E. May B.R. Westley B. Drumm Helicobacter pylori interacts with the human single-domain trefoil protein TFF1 Proc Natl Acad Sci USA 101 2004 7409-7414
50. A.J. FitzGerald M. Pu T. Marchbank B.R. Westley F.E.B. May J. Boyle M. Yadollahi-Farsani S. Ghosh R.J. Playford Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis Peptides 25 2004 793-801